Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | KOD |
---|---|---|
09:32 ET | 6918 | 3.24 |
09:34 ET | 200 | 3.25 |
09:36 ET | 1200 | 3.31 |
09:38 ET | 600 | 3.36 |
09:39 ET | 600 | 3.36 |
09:41 ET | 2470 | 3.42 |
09:43 ET | 3690 | 3.35 |
09:45 ET | 7687 | 3.37 |
09:48 ET | 759 | 3.36 |
09:50 ET | 1504 | 3.35 |
09:52 ET | 600 | 3.33 |
09:54 ET | 535 | 3.32 |
09:56 ET | 100 | 3.31 |
09:57 ET | 100 | 3.32 |
09:59 ET | 1069 | 3.33 |
10:03 ET | 430 | 3.3497 |
10:06 ET | 1058 | 3.37 |
10:08 ET | 392 | 3.37 |
10:10 ET | 11525 | 3.33 |
10:12 ET | 200 | 3.3 |
10:14 ET | 100 | 3.3 |
10:15 ET | 598 | 3.31 |
10:17 ET | 359 | 3.32 |
10:21 ET | 200 | 3.33 |
10:24 ET | 550 | 3.325 |
10:26 ET | 668 | 3.32 |
10:28 ET | 1420 | 3.3371 |
10:30 ET | 244 | 3.34 |
10:32 ET | 1284 | 3.341 |
10:33 ET | 200 | 3.35 |
10:35 ET | 200 | 3.35 |
10:37 ET | 920 | 3.3405 |
10:39 ET | 200 | 3.345 |
10:42 ET | 100 | 3.36 |
10:44 ET | 4100 | 3.36 |
10:46 ET | 100 | 3.39 |
10:48 ET | 100 | 3.39 |
10:50 ET | 100 | 3.38 |
10:51 ET | 2944 | 3.37 |
10:53 ET | 200 | 3.3612 |
10:55 ET | 1100 | 3.35 |
10:57 ET | 1782 | 3.3301 |
11:04 ET | 100 | 3.33 |
11:06 ET | 400 | 3.3349 |
11:08 ET | 750 | 3.34 |
11:09 ET | 5432 | 3.36 |
11:11 ET | 3352 | 3.3699 |
11:13 ET | 1700 | 3.375 |
11:15 ET | 103 | 3.3898 |
11:18 ET | 200 | 3.39 |
11:20 ET | 805 | 3.39 |
11:22 ET | 100 | 3.39 |
11:24 ET | 12170 | 3.3841 |
11:26 ET | 537 | 3.39 |
11:27 ET | 100 | 3.39 |
11:29 ET | 200 | 3.4 |
11:31 ET | 2071 | 3.36 |
11:33 ET | 897 | 3.35 |
11:38 ET | 1200 | 3.3499 |
11:40 ET | 1500 | 3.31 |
11:44 ET | 100 | 3.31 |
11:51 ET | 9231 | 3.3299 |
11:54 ET | 11992 | 3.33 |
11:56 ET | 4600 | 3.32 |
12:03 ET | 637 | 3.2737 |
12:07 ET | 1392 | 3.265 |
12:18 ET | 100 | 3.27 |
12:20 ET | 200 | 3.27 |
12:21 ET | 100 | 3.27 |
12:23 ET | 100 | 3.27 |
12:25 ET | 300 | 3.27 |
12:27 ET | 100 | 3.27 |
12:32 ET | 800 | 3.23 |
12:36 ET | 2319 | 3.205 |
12:39 ET | 500 | 3.2071 |
12:41 ET | 300 | 3.2 |
12:43 ET | 100 | 3.21 |
12:50 ET | 300 | 3.19 |
12:59 ET | 100 | 3.19 |
01:01 ET | 300 | 3.19 |
01:06 ET | 1586 | 3.18 |
01:12 ET | 3584 | 3.13 |
01:19 ET | 3038 | 3.16 |
01:21 ET | 300 | 3.17 |
01:24 ET | 900 | 3.18 |
01:26 ET | 200 | 3.18 |
01:28 ET | 200 | 3.18 |
01:30 ET | 2427 | 3.18 |
01:33 ET | 161 | 3.172 |
01:39 ET | 100 | 3.18 |
01:42 ET | 8824 | 3.185 |
01:44 ET | 1400 | 3.2 |
01:46 ET | 200 | 3.22 |
01:48 ET | 200 | 3.23 |
01:50 ET | 1926 | 3.22 |
01:51 ET | 100 | 3.22 |
02:02 ET | 100 | 3.22 |
02:04 ET | 700 | 3.23 |
02:06 ET | 100 | 3.23 |
02:08 ET | 200 | 3.23 |
02:09 ET | 100 | 3.23 |
02:11 ET | 100 | 3.23 |
02:13 ET | 100 | 3.23 |
02:18 ET | 100 | 3.23 |
02:22 ET | 300 | 3.23 |
02:24 ET | 200 | 3.24 |
02:26 ET | 100 | 3.25 |
02:27 ET | 100 | 3.25 |
02:29 ET | 100 | 3.25 |
02:33 ET | 100 | 3.25 |
02:38 ET | 200 | 3.25 |
02:40 ET | 100 | 3.25 |
02:42 ET | 7306 | 3.25 |
02:44 ET | 1278 | 3.23 |
02:45 ET | 124 | 3.235 |
02:49 ET | 300 | 3.22 |
02:51 ET | 522 | 3.22 |
02:54 ET | 400 | 3.25 |
02:56 ET | 400 | 3.25 |
02:58 ET | 300 | 3.25 |
03:00 ET | 618 | 3.25 |
03:02 ET | 600 | 3.235 |
03:03 ET | 300 | 3.25 |
03:05 ET | 300 | 3.25 |
03:09 ET | 100 | 3.235 |
03:12 ET | 100 | 3.25 |
03:14 ET | 100 | 3.25 |
03:18 ET | 1528 | 3.24 |
03:21 ET | 800 | 3.24 |
03:27 ET | 800 | 3.24 |
03:30 ET | 200 | 3.25 |
03:32 ET | 1895 | 3.24 |
03:34 ET | 100 | 3.25 |
03:36 ET | 100 | 3.24 |
03:38 ET | 200 | 3.25 |
03:39 ET | 600 | 3.25 |
03:41 ET | 300 | 3.25 |
03:43 ET | 100 | 3.25 |
03:45 ET | 11649 | 3.25 |
03:48 ET | 200 | 3.245 |
03:54 ET | 995 | 3.25 |
03:56 ET | 14590 | 3.26 |
03:57 ET | 11387 | 3.25 |
03:59 ET | 14524 | 3.24 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Kodiak Sciences Inc | 167.1M | -0.7x | --- |
Outlook Therapeutics Inc | 165.5M | -0.6x | --- |
Galectin Therapeutics Inc | 169.0M | -3.6x | --- |
X4 Pharmaceuticals Inc | 169.6M | -1.4x | --- |
Atossa Therapeutics Inc | 163.5M | -5.6x | --- |
Rezolute Inc | 161.7M | -3.6x | --- |
Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy, the cause of blindness in working-age patients in the developed world, and wet age-related macular degeneration, the cause of blindness in elderly patients. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $167.1M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 52.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.42 |
EPS | $-4.44 |
Book Value | $5.06 |
P/E Ratio | -0.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.